CutisPharma announces FDA approval for Firvanq
CutisPharma reported that the U.S. Food and Drug Administration has approved Firvanq (vancomycin hydrochloride) for oral solution, for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains.